Publication
Medical Cannabis Access Programme
From Department of Health
Published on
Last updated on
On 26th June 2019, the Minister for Health signed legislation to allow for the operation of the Medical Cannabis Access Programme on a pilot basis for five years.
The Programme will facilitate access to cannabis-based products for medical use in line with legislation and with the clinical guidance for the scheme.
The signing of the legislation underpinning the Access Programme allows for commencement of the operation of the Access Programme, the first stage of which is for potential suppliers to apply to have their medical cannabis products considered for suitability for medical use under the scheme.
Cannabis products will only be listed in Schedule 1 of the Regulations once they have been considered as suitable for use under the Medical Cannabis Access Programme.
The Medical Cannabis Access Programme will make it possible for a medical consultant to prescribe a cannabis-based treatment for a patient under his or her care for the following medical conditions, where the patient has failed to respond to standard treatments:
- Spasticity associated with multiple sclerosis
- Intractable nausea and vomiting associated with chemotherapy
- Severe, refractory (treatment-resistant) epilepsy.
Work on the establishment of Programme began in March 2017, on foot of the conclusions from the Health Products Regulatory Authority’s (HPRA) expert report Cannabis for Medical Use – A Scientific Review, which was prepared at the request of the Minister for Health. Following publication of the report, Minister Harris established an Expert Reference Group to advise on the development of a Medical Cannabis Access Programme.
The Group developed clinical guidelines for the Programme, which are available below:
Clinical Guidance on Cannabis for Medical Use
The Medical Cannabis Access Programme is not required or intended for authorised medicinal products but rather is to facilitate access to cannabis-based products that are not authorised as medicines but are of a standardised quality and meet an acceptable level of quality assurance during their manufacturing process.
Download link for
Download
View the file
View
Once the Medical Cannabis Access Programme commences the HSE will establish and maintain a Register to facilitate the enrolment and recording of certain data including patient identifiers (in anonymised format), prescribers enrolled in the Programme, as well as prescribed / supplied medical cannabis products.
Please note: The MCAP register is not currently operational. Patients and Healthcare Professionals are advised to consult this page for updates which will be published when available.
The underpinning secondary legislation for the Programme includes:
- The Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2021, update to Schedule 1. (S.I. No. 577 of 2021)
- The Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2019, update to Schedule 1.
- The Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 set out the legal provisions for the operation of the Medical Cannabis Access Programme and the legal obligations for healthcare professionals and commercial operators
- The Misuse of Drugs (Designation) (Amendment) Order 2019 amends S.I. No. 533 of 2017, Misuse of Drugs (Designation) Order 2017 by removing from the scope of the Order certain cannabis-based products that will be permitted for use under the Medical Cannabis Access Programme
- The Misuse of Drugs (Amendment) Regulations 2019 amends S.I. No. 173 of 2017 – Misuse of Drugs Regulations 2017 to reschedule certain acceptable cannabis-based products for medical use under the Medical Cannabis Access Programme from Schedule 1 to Schedule 2.
The following specified controlled drug products (cannabis-based products) have been accepted as being suitable for use under the Medical Cannabis Access Programme:
| Name of Cannabis product or preparation and brand name | Dosage form | Concentration of THC (percentage, weight/weight or weight/volume) | Name of manufacturer | |
| Aurora High CBD Oil Drops | Oral solution | Less than 3% w/v (< 30mg/ml) This product also contains cannabidiol (CBD) 60% w/v (600mg/ml) | Aurora Cannabis Enterprises Inc., 4439 Township Road 304, Cremona, Alberta, Canada, T0M 0R0 | |
| CannEpil ™ | Oral solution 0.5% w/v (5mg/ml) This product also contains cannabidiol (CBD) | 10% w/v (100 mg/ml) | MGC Pharmaceuticals d.o.o., Kamniška ulica 29, 1000, Ljubljana, Slovenia | |
| Tilray Oral Solution THC10:CBD10 25ml | Oral solution | 1% w/v (10mg/ml) This product also contains cannabidiol (CBD) 1% w/v (10mg/ml) | Tilray Portugal Unipessoal Lda., Zona Industrial de Cantanhede, Lote 121, Cantanhede, 3060-197, Portugal. | |
| Aurora Sedamen Softgels | Capsules | 5mg/capsule This product also contains cannabidiol (CBD) less than 0.2mg/capsule | Aurora Cannabis Enterprises Inc. 4250 14th Avenue, Markham, Ontario, Canada L3R 0J3 | |
| Oleo Bedrobinol | Dried Flower | 13.5% w/w (135mg/g) This product also contains cannabidiol (CBD) less than 1.0% w/w (less than 10mg/g) | Bureau voor Medicinale Cannabis Postbus 16114 2500 BC DEN HAAG The Netherlands | |
| Oleo Bedrocan | Dried Flower | 22% w/w (220mg/g) This product also contains cannabidiol (CBD) less than 1.0% w/w (less than 10mg/g) | Bureau voor Medicinale Cannabis Postbus 16114 2500 BC DEN HAAG The Netherlands |
Based on the information provided by applicants, the products listed in the table above are considered by the Health Products Regulatory Authority (HPRA) to meet the criteria in parts (a) – (f) of the definition of a ‘specified controlled drug’ set out in the Misuse of Drugs (Prescription and control of supply of cannabis for medical use) Regulations 2019 and, accordingly, can be considered for inclusion in Schedule 1 to those Regulations.
The Minister for Health has accepted the HPRA’s advice and as these products are in line with the clinical guidance for the scheme, they have now been added to Schedule 1 of the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019, which can be found at the following link: https://www.irishstatutebook.ie/eli/2021/si/557/made/en/print
For further educational information on accepted specified controlled drugs, healthcare professionals should contact the relevant manufacturer at the following contact email:
| Name of Manufacturer | Contact Email |
| Aurora Cannabis Enterprises Inc., 4439 Township Road 304, Cremona, Alberta, Canada, T0M 0R0 | clientcare@auroramj.com |
| MGC Pharmaceuticals d.o.o., Kamniška ulica 29, 1000, Ljubljana, Slovenia | dan@pacelli.ie |
| Tilray Portugal Unipessoal Lda., Zona Industrial de Cantanhede, Lote 121, Cantanhede, 3060-197, Portugal. | EUdocumentrequest@tilray.com |
| Bureau voor Medicinale Cannabis Postbus 16114 2500 BC DEN HAAG The Netherlands | info@oleo.ie |
Cannabis products that can be used in the Medical Cannabis Access Programme are defined as ‘specified controlled drugs’ in legislation and the definition outlines the specific requirements for those products.
Only products included in the schedule of specified controlled drugs can be prescribed by medical consultants under the Medical Cannabis Access Programme.
The criteria cannabis products must meet in order to be considered by the Minister for inclusion on the schedule are set out in the legislation and can be found in the operator guidance issued by the HPRA
Each cannabis-based product for medical use must be accompanied by a specific patient information leaflet, as referenced in the HPRA's Operator Guidance (see above). It is essential that all suppliers of cannabis-based products ensure that every patient receives this leaflet with their prescribed product. Please click here to view and download the Patient Information Leaflet.
Details on how to apply for a licence to possess, supply or import medical cannabis products for use under the Medical Cannabis Access Programme in accordance with the requirements for schedule 2 products in the Misuse of Drugs Regulations 2017 can be found in the operator guidance issued by the HPRA
For further information operators should contact the HPRA at controlleddrugs@hpra.ie
Having consulted the above Q&A, the secondary legislation underpinning the Programme - the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019, and the Clinical Guidance document, if you do not find the information you require please submit your query to: controlled_drugs@health.gov.ie